Home Page
13:36:08 EST Wed 26 Nov 2014
Enter Symbol
or Name
USA
CA



SPECTRUM PHARMACEUTICALS INC
Symbol U : SPPI
Recent Sedar Documents

Gainey McKenna & Egleston Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. -- SPPI

2013-03-22 19:00 ET - News Release

NEW YORK, March 22, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of purchasers of securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (Nasdaq:SPPI) between August 8, 2012 and March 12, 2013, inclusive (the "Class Period"), seeking remedies under the federal securities laws.

The Complaint alleges that, during the Class Period, Defendants violated the federal securities laws by disseminating false and misleading statements to the investing public in connection with FUSILEV, and concealed the impact that the increased availability of competing generic drug (leucovorin) would have on sales of FUSILEV.  As a result of Defendants' false and misleading statements, Spectrum's stock traded at artificially inflated prices during the Class Period, reaching a high of $13.05 per share on September 18, 2012.

If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2013. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.

Attorney Advertising -- Prior results do not guarantee or predict a similar outcome with respect to any future matter.  Please visit our website at http://www.gme-law.com for more information about the firm. 

CONTACT: Gainey McKenna & Egleston
         (212) 983-1300

© 2014 Canjex Publishing Ltd. All rights reserved.